A phase I clinical trial employing a novel highly selective EGFR-targeting TKI drug icotinib attempted to study the combination of the EGFR TKI drug with IMRT in NPC patients [416]. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.